Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vital Therapies Joins the Russell 3000 Index®
SAN DIEGO , June 25, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD ® , a cell-based therapy targeting the treatment of acute forms of liver failure, announced it has been added as a member of the broad-market Russell 3000 ® Index, effective
View HTML
Toggle Summary Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO , June 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported a grant under its Amended and Restated 2017 Inducement Equity Incentive Plan to a
View HTML
Toggle Summary Vital Therapies to Present at the Jefferies 2018 Global Healthcare Conference
SAN DIEGO , June 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that Russell J. Cox , Chief Executive Officer, will present at the Jefferies
View HTML
Toggle Summary Vital Therapies Hosting Analyst R&D Day Today
SAN DIEGO , May 24, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will host a live webcast of its Analyst R&D Day today beginning at 11:00 a.m.
View HTML
Toggle Summary Vital Therapies to Host Analyst R&D Day on May 24, 2018
SAN DIEGO , May 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will host a live webcast of its Analyst R&D Day on Thursday, May 24, 2018 beginning at 11:00 a.m.
View HTML
Toggle Summary Vital Therapies Announces First Quarter 2018 Financial Results
- VTL-308 Enrollment Completed with 151 Subjects - On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO , May 08, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms
View HTML
Toggle Summary Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call with Webcast
SAN DIEGO , April 26, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2018 financial results after the market closes on Tuesday, May
View HTML
Toggle Summary Vital Therapies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , April 25, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported grants under its Amended and Restated 2017 Inducement Equity Incentive Plan to
View HTML
Toggle Summary Vital Therapies Announces VTL-308 Reaches Enrollment Target of 150 Subjects
Topline Results for VTL-308 Expected in the Third Quarter of 2018 SAN DIEGO , March 22, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the
View HTML
Toggle Summary Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results
- VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12 - On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO , March 13, 2018 (GLOBE NEWSWIRE) --   Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy
View HTML